Press Releases
Date picker
Category
Results per page
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 30th June 2018
PERIOD 1 JAN - 30 JUNE 2018 IN BRIEF• Net sales for the period amounted to MSEK 0.0 (0.1 million). Sales for the second quarter were 0.0 MEK (0.1 M)• R & D expenses…
A new patent application from Kancera lays the foundation for the development of additional drug candidates in the Fractalkine project
This is a translation of the Swedish press release published 2018-07-06. Kancera AB (publ) hereby announces that unique blockers (antagonists) of the Fractalkine system have been patented. Kancera intends to…
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 31st March 2018
PERIOD 1 JAN - 31 MARCH 2018 IN BRIEF• Net sales amounted to SEK 0 million (0 million)• R & D expenses amounted to SEK 11.8 million (8.3 M)• Operating profit amounted to…
Time plan for Kancera’s rights issue
Regulatory
Today, Friday, April 27, 2018 is the last day of trading in Kancera's share, including the right to participate in the rights issue.Otherwise, the following time plan applies (dates refer…
Kancera provides operational update for HDAC6 and ROR projects
Kancera AB intends to provide new information about the company's pharmaceutical projects during April in a prospectus that forms part of a proposed new share issue. For this reason, Kancera…
Kancera proposes a preferential rights issue of MSEK 60 to fund the continued clinical development of KAND567
This is a translation of a Press Release in Swedish Stockholm 2018-04-03
YEAR END REPORT KANCERA AB (publ) 1st January – 31st December 2017
Regulatory
PERIOD 1 JAN - 31 DEC 2017 IN BRIEF• Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R…
Kancera reports results from clinical Phase I study and strategy for continued development of KAND567
Kancera AB (publ) hereby reports results from a Phase I study in healthy subjects with the immunoregulating drug candidate KAND567. The study shows that KAND567 is safe and well-tolerated up…
Kancera reports that clinical Phase I study has been completed in the Fractalkine project
Kancera AB (publ) reports that the Phase I study in the Fractalkine project has been completed in accordance with study protocols. In the study, drug characteristics, safety and tolerability have…
Kancera acquires additional rights to the Fractalkine project
Kancera AB (publ) has previously announced that the company controls patents and rights to the Fractalkine project, including KAND567, in all diseases except lung diseases. Agreements with AstraZeneca AB and…